Revolution Medicines (NASDAQ: RVMD) CDO sells 6,309 shares under preset plan

What happened

Revolution Medicines, Inc. (NASDAQ: RVMD) Chief Development Officer Alan B. Sandler sold 6,309 shares on 2026-09-29.

Prices ran from $200.82 to $204.72 a share, and the sale totaled about $1.28 million.

The Form 4 also shows Sandler exercised 6,000 stock options at $58.84 each on the same date.

Before the sales began, the exercise lifted Sandler's direct holding to 58,868 shares.

The sale was executed in five blocks, with weighted average prices of $200.8188, $201.7239, $202.8127, $203.9074 and $204.7224.

After the transactions, Sandler held 52,559 shares.

The filing says the trades were made under a Rule 10b5-1 trading plan adopted on June 30, 2026.

Key numbers

Metric	Latest	Change	Source
Shares sold	6,309 shares		SEC Form 4
Sale price range	$200.82 to $204.72 per share		SEC Form 4
Proceeds	about $1.28 million		SEC Form 4
Shares held after sale	52,559 shares		SEC Form 4
Stock options exercised	6,000 options		SEC Form 4

Read more: Revolution Medicines (RVMD) stock analysis and investment case

Why it matters

OptimistFi's case is that Revolution Medicines' value hinges on clinical proof-points and non-dilutive partnerships for its RAS-addicted oncology programs.

It also depends on funding steep development spending from a shrinking cash runway.

This filing is mixed because it updates Sandler's ownership after a sale and exercise, but it does not change the company's clinical or financing story.

The 6,309 shares were about 10.7% of Sandler's 58,868-share holding before the trade.

That makes the sale a meaningful trim within the position.

The caveat is that the filing says the sales were made under a Rule 10b5-1 plan adopted on June 30, 2026, so the trade can reflect a preset schedule.

The option exercise was at a $58.84 strike, which keeps the filing focused on ownership changes rather than an open-market purchase.

The filing is an ownership update, not a new operating signal.

Browse: stock research on every company OptimistFi covers

What's next

The same option expires on 11/01/2035, and 25% vests on the first year anniversary measured from September 29, 2025.

One forty-eighth of the shares vests on each monthly anniversary after that.

The filing also says the option will be fully vested and exercisable as of the fourth anniversary of the vesting commencement date.

Future Form 4 filings under the same plan will show whether Sandler's stake keeps moving lower on that preset schedule.

That makes the vesting path the clearest follow-on item in the filing.

More from OptimistFi